Compare Crispr Therapeutics AG (CRSP) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Huntington Bancshares Incorporated — how do they compare? Crispr Therapeutics AG trades at $53.75 (market cap $4.88B), while Huntington Bancshares Incorporated trades at $15.31 (market cap $31.04B). The key difference: Huntington Bancshares Incorporated is far larger — about 6.4× Crispr Therapeutics AG's market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Huntington Bancshares Incorporated for 52 Days on average.
| CRSP | HBAN | |
|---|---|---|
Market Cap | $4.88B | $31.04B |
Volume | 2,861,747 | 23,864,172 |
Sector | Health | Financials |
52-Week High | $74.92 | $19.27 |
52-Week Low | $44.34 | $15.02 |
Typical Hold Time | 77 Days | 52 Days |
Enterprise Value | $3.30B | $49.57B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Huntington Bancshares (HBAN) trades at $15.28, up 0.73% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bearish technical signal with key support at $15 and resistance at $16, while fundamentals show a P/E of 11.82 and net income margin of 24.77%. Recent news highlights a cut in 2027 earnings outlook due to interest rate pressures, though the company maintains shareholder returns via dividends and buybacks.
The outlook for HBAN is cautious, with near-term headwinds from margin compression and loan growth challenges offset by a solid balance sheet and analyst consensus price target of $19.60. Risks include persistent interest rate pressures and competitive lending markets, but the stock offers value appeal with a dividend yield and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
